Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus etoposide in advanced small cell lung cancer
NCT03389087Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03389087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389087.